78F0 Stock Overview
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Freeline Therapeutics Holdings plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.00 |
| 52 Week High | US$6.00 |
| 52 Week Low | US$6.00 |
| Beta | 0.66 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 0% |
Recent News & Updates
Recent updates
Shareholder Returns
| 78F0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.8% | -1.2% |
| 1Y | n/a | -19.8% | 1.8% |
Price Volatility
| 78F0 volatility | |
|---|---|
| 78F0 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 152 | Michael Parini | www.freeline.life |
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy.
Freeline Therapeutics Holdings plc Fundamentals Summary
| 78F0 fundamental statistics | |
|---|---|
| Market cap | €26.12m |
| Earnings (TTM) | -€46.17m |
| Revenue (TTM) | €575.10k |
45.4x
P/S Ratio-0.6x
P/E RatioIs 78F0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 78F0 income statement (TTM) | |
|---|---|
| Revenue | US$622.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$622.00k |
| Other Expenses | US$50.55m |
| Earnings | -US$49.93m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -11.45 |
| Gross Margin | 100.00% |
| Net Profit Margin | -8,027.65% |
| Debt/Equity Ratio | 0% |
How did 78F0 perform over the long term?
See historical performance and comparison